BackGyre Therapeutics Overview

Gyre Therapeutics Profit Margin

Gyre Therapeutics (GYRE) has a profit margin of -21.4%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

-12.31%
↓ 140.35% YoY

As of Sep 2026

Annual Profit Margin (TTM)

-21.40%
↓ 251.01% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Gyre Therapeutics (GYRE) FAQ

Gyre Therapeutics (GYRE) currently reports a profit margin of -21.4% as of September 2026. That compares with 14.17% in the prior-year period — down 251.0% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Gyre Therapeutics's profit margin history and peer comparisons.

Gyre Therapeutics's profit margin decreased from 14.17% to -21.4% — a 251.0% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gyre Therapeutics's profit margin of -21.4% is lower than the Healthcare sector average of 17.63%. That is roughly 221.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Gyre Therapeutics's current -21.4% should be judged against Healthcare norms (sector average: 17.63%) and against GYRE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -21.4%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Gyre Therapeutics, and consider following GYRE for alerts when major investors trade the stock.